 |
PDBsum entry 1hfg
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
FEBS Lett
489:171-175
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10).
|
|
M.P.Crump,
E.Elisseeva,
J.Gong,
I.Clark-Lewis,
B.D.Sykes.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II that
has been shown to be a broad range human chemokine receptor antagonist. Two
N-terminal peptides, vMIP-II(1-10) and vMIP-II(1-11)dimer (dimerised through
Cys11) were synthesised. Both peptides are shown to bind the CXC chemokine
receptor 4 (CXCR4). vMIP-II(1-10) was 1400-fold less potent than the native
protein whilst the vMIP-II(1-11)dimer was only 180-fold less potent. In
addition, both peptides are CXCR4 antagonists. Through analysis of non-standard,
long mixing time two-dimensional nuclear Overhauser enhancement spectroscopy
experiments, 13C relaxation data and amide chemical shift temperature gradients
for the N-terminus of vMIP-II, we show that this region populates a turn-like
structure over residues 5-8, both in the presence and absence of the full
protein scaffold. This major conformation is likely to be in fast exchange with
other conformational states but it has not previously been detected in monomeric
chemokine structures. This and other studies [Elisseeva et al. (2000) J. Biol.
suggest that there may be a link between the structuring
of the short N-terminal chemokine peptides and their ability to bind their
receptor.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. Receptor binding of vMIP-II and SDF-1 based
N-terminal peptides and chemotaxis inhibition by
vMIP-II(1–10). A: Competition for specific binding of
^125I-SDF-1 (4 nM) to CEM cells by SDF-1 (open circle),
SDF(1–9) monomer (open triangle), SDF(1–9)dimer (closed
triangle), vMIP-II(1–10) (open square), vMIP-II(1–11)dimer
(closed square) and N-MDC (square with cross). The data for the
N-terminal peptides of IP-10, eotaxin and eotaxin-2 are not
shown. The results are representative of duplicate experiments.
B: CEM cell migration induced by concentrations of
SDF(1–9)dimer (closed circle) and the antagonist
vMIP-II(1–10) (open triangle). Data are the means of ±S.D. of
duplicate determinations from two separate experiments.
|
 |
Figure 2.
Fig. 2. Solution structure of the vMIP-II(1–10). A bundle
of 55 calculated structures is shown superimposed on the average
structure. Residues Trp5 through to Pro8 corresponding to the
region of partial structuring are annotated.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the Federation of European Biochemical Societies:
FEBS Lett
(2001,
489,
171-175)
copyright 2001.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.N.Langelaan,
P.Ngweniform,
and
J.K.Rainey
(2011).
Biophysical characterization of G-protein coupled receptor-peptide ligand binding.
|
| |
Biochem Cell Biol,
89,
98.
|
 |
|
|
|
|
 |
H.Shim,
S.Oishi,
and
N.Fujii
(2009).
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.
|
| |
Semin Cancer Biol,
19,
123-134.
|
 |
|
|
|
|
 |
X.Liang
(2008).
CXCR4, inhibitors and mechanisms of action.
|
| |
Chem Biol Drug Des,
72,
97.
|
 |
|
|
|
|
 |
C.M.Slupsky,
L.Spyracopoulos,
V.K.Booth,
B.D.Sykes,
and
M.P.Crump
(2007).
Probing nascent structures in peptides using natural abundance 13C NMR relaxation and reduced spectral density mapping.
|
| |
Proteins,
67,
18-30.
|
 |
|
|
|
|
 |
D.Raman,
P.J.Baugher,
Y.M.Thu,
and
A.Richmond
(2007).
Role of chemokines in tumor growth.
|
| |
Cancer Lett,
256,
137-165.
|
 |
|
|
|
|
 |
Y.Becker
(2007).
The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes--a review, hypothesis and implications for treatment.
|
| |
Virus Genes,
34,
93.
|
 |
|
|
|
|
 |
C.Esche,
C.Stellato,
and
L.A.Beck
(2005).
Chemokines: key players in innate and adaptive immunity.
|
| |
J Invest Dermatol,
125,
615-628.
|
 |
|
|
|
|
 |
O.K.Baryshnikova,
J.K.Rainey,
and
B.D.Sykes
(2005).
Nuclear magnetic resonance studies of CXC chemokine receptor 4 allosteric peptide agonists in solution.
|
| |
J Pept Res,
66,
12-21.
|
 |
|
|
|
|
 |
A.Liston,
and
S.McColl
(2003).
Subversion of the chemokine world by microbial pathogens.
|
| |
Bioessays,
25,
478-488.
|
 |
|
|
|
|
 |
E.J.Fernandez,
and
E.Lolis
(2002).
Structure, function, and inhibition of chemokines.
|
| |
Annu Rev Pharmacol Toxicol,
42,
469-499.
|
 |
|
|
|
|
 |
N.Zhou,
Z.Luo,
J.Luo,
D.Liu,
J.W.Hall,
R.J.Pomerantz,
and
Z.Huang
(2001).
Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.
|
| |
J Biol Chem,
276,
42826-42833.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |